MR. MICHAEL THOMAS MORRIS PA-C
Prescription History 1962519439
Physician Assistant in Richmond, TX

NPI Status: Active since August 23, 2006

Contact Information

7101 W GRAND PKWY S
SUITE 180
RICHMOND, TX
ZIP 77407
Phone: (832) 304-2309
Fax: (713) 439-7995

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. MICHAEL THOMAS MORRIS PA-C, an active Physician Assistant specialist practicing in Richmond, TX. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 103 documented patient claims. Among these therapy options, the most frequently utilized medication is Azelastine Hcl, which accounts for 49 claims alone.

Medication Index


Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 49
30-Day Fills 49.0
Days Supply 1,319
TX State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills56.6
Peer Average Days Supply1,652
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 40.0% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,382.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.21

State Avg Cost Per Claim

$45.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 60
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply287
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.75

State Avg Cost Per Claim

$9.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 57
TX State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.7
Peer Average Days Supply288
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $61.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.61

State Avg Cost Per Claim

$8.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 170
TX State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.7
Peer Average Days Supply495
Conservative Utilization

This provider writes prescriptions for this formulation 45.2% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $358.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.09

State Avg Cost Per Claim

$23.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Lagevrio (Eua)

Generic Formulation: MolnupiravirSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 70
TX State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.3
Peer Average Days Supply112
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $143.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.25

State Avg Cost Per Claim

$10.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with molnupiravir. Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. MICHAEL THOMAS MORRIS PA-C provides transparency into local medical care patterns within Richmond, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.